Provided by Tiger Trade Technology Pte. Ltd.

Invesco Nasdaq Biotechnology ETF

34.62
+0.99512.96%
Post-market: 34.620.00000.00%19:30 EDT
Volume:31.48K
Turnover:1.09M
Market Cap:111.48M
PE:- -
High:34.68
Open:33.80
Low:33.71
Close:33.62
52wk High:36.84
52wk Low:25.00
Shares:3.22M
Float Shares:3.22M
Volume Ratio:0.39
T/O Rate:0.98%
Dividend:0.39
Dividend Rate:1.13%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Quantum Computing is Having a Moment. What to Know About the Hottest Sector After AI.

Dow Jones
·
Oct 02

Regeneron Pharmaceuticals, Inc. : Jefferies Raises Target Price to $930 from $870

THOMSON REUTERS
·
Oct 02

More Upside Awaits for Gilead Sciences Stock. Stay Invested.

Dow Jones
·
Oct 02

Vortex Energy Expands Saskatchewan Portfolio with Meadows Project Acquisition

TIPRANKS
·
Oct 02

Vertex adds AI-focused independent director to board

TIPRANKS
·
Oct 02

Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know

TradingKey
·
Oct 02

S&P 500 Top and Bottom Performing Stocks at About 03:30 P.m. EDT

Reuters
·
Oct 02

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know

TradingKey
·
Oct 02

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-10-01

Reuters
·
Oct 02

Regeneron price target raised to $930 from $870 at Jefferies

TIPRANKS
·
Oct 02

Amgen’s Pediatric Psoriasis Study in Japan Wraps Up, Setting the Stage for Otezla Growth

TIPRANKS
·
Oct 02

Expanded Sanofi agreement particularly favorable for Regeneron, says TD Cowen

TIPRANKS
·
Oct 02

Walt Disney, Amgen Share Losses Lead Dow's 150-Point Fall

Dow Jones
·
Oct 02

Regeneron says COURAGE trial confirms trevogrumab prevents muscle loss

TIPRANKS
·
Oct 01

Regeneron Pharmaceuticals, - 9-Month Median Duration of Response Observed at 800 Mg Ubamatamab Dose

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Ubamatamab Shows 73% Objective Response Rate and 11-Month Median Pfs in Lgsoc Patients

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Serious Teaes Grade 3+ in 21% of Lgsoc Patients; Traes in 74%; Neutropenia, Anemia, Elevated Liver Enzymes

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - to Advance Ubamatamab into Confirmatory Phase 3 Trial for Lgsoc

THOMSON REUTERS
·
Oct 01

Ubamatamab (Muc16xcd3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (Lgsoc)

THOMSON REUTERS
·
Oct 01

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

GlobeNewswire
·
Oct 01